The Journal of PHARMACOLOGY And Experimental Therapeutics

Correction to "Molecular targets for antiviral agents"

In the above article [De Clerq E (2001) *J Pharmacol Exp Ther* **297:**1–10], the structure that pertains to neplanocin A and 3-deazaneplanocin in Fig. 2 was presented incorrectly. The corrected figure follows. The author regrets any confusion or inconvenience caused by this error.



Fig. 2. Prototype (representative) antiviral agents. Polyanionic substances: PVAS and PVS. Receptor antagonists: bicyclam AMD3100. NRTIs: stavudine (d4T). NNRTIs: emivirine (MKC 442). Nucleoside analogs: valaciclovir and brivudin. Acyclic nucleoside phosphonates: cidofovir, adefovir, and tenofovir. IMP dehydrogenase inhibitors: EICAR and mycophenolic acid. SAH hydrolase inhibitors: neplanocin A derivatives.